Showing results (401-410 of 448) with videos related to

Sort By:
Pageof 45
Investigational New Drugs|January 7, 2021
Phase II study of the histone deacetylase inhibitor vorinostat (Suberoylanilide Hydroxamic Acid; SAHA) in recurrent or metastatic transitional cell carcinoma of the urothelium - an NCI-CTEP sponsored: California Cancer Consortium trial, NCI 6879David I Quinn, Denice D Tsao-Wei, Przemyslaw Twardowski, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 9, 2005
Paclitaxel-based high-dose chemotherapy with autologous stem cell rescue for relapsed germ cell cancerKim A Margolin, James H Doroshow, Paul Frankel, et al.
Kidney International|April 13, 2006
Longer treatment time and slower ultrafiltration in hemodialysis: associations with reduced mortality in the DOPPSR Saran, J L Bragg-Gresham, N W Levin, et al.
Frontiers in Immunology|March 20, 2024
The NF-κB RelA transcription factor is not required for CD8+ T-cell function in acute viral infection and cancerAllison Voisin, Maud Plaschka, Marlène Perrin-Niquet, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 17, 2003
Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: dose-limiting toxicity and pharmacokineticsRobert J Morgan, James H Doroshow, Timothy Synold, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 15, 2006
A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastasesPrimo N Lara, Walter M Stadler, Jeff Longmate, et al.
European Urology|April 21, 2023
Bone Biomarkers and Subsequent Survival in Men with Hormone-sensitive Prostate Cancer: Results from the SWOG S1216 Phase 3 Trial of Androgen Deprivation Therapy with or Without OrteronelPrimo N Lara, Edward Mayerson, Erik Gertz, et al.
Cancer Treatment and Research Communications|July 13, 2019
Bone turnover biomarkers identify unique prognostic risk groups in men with castration resistant prostate cancer and skeletal metastases: Results from SWOG S0421P N Lara, M Plets, C Tangen, et al.
Clinical and Translational Medicine|October 11, 2024
Reduction of myeloid-derived suppressor cells in prostate cancer murine models and patients following white button mushroom treatmentXiaoqiang Wang, Shoubao Ma, Przemyslaw Twardowski, et al.
Harmful Algae|May 13, 2021
Dynamics of microcystins and saxitoxin in the Indian River Lagoon, FloridaAbdiel E Laureano-Rosario, Malcolm McFarland, David J Bradshaw, et al.
Pageof 45